Sygnature Discovery selected as partner in European drug discovery project7 February 2013 Nottingham-based Sygnature Discovery has been selected to be an SME partner in the €196m European Lead Factory project, which was launched today by an international consortium of 30 partners (see MTB Europe news: BioCity Scotland to be UK hub for €196m European drug discovery project.) As part of the European Lead Factory, the 7 participating pharmaceutical companies will contribute at least 300,000 chemical compounds from their corporate chemical collections. A library of an estimated additional 200,000 novel compounds will be developed jointly by academia and SMEs. The chemistry part of the consortium consists of 5 SMEs:
These companies aim to contribute an estimated 200,000 novel compounds to the Joint Compound Collection. Proposals will be submitted to a transparent selection and validation process addressing several criteria such as novelty, diversity potential, innovative design, synthetic tractability and other. Once approved, the SMEs together with the academic institutions will seamlessly translate successful scaffolds into high quality compound libraries to be shipped to the consortium’s HTS facilities. Dr Simon Hirst, Chief Executive Officer, Sygnature Discovery said: “Sygnature is delighted to be a part of this unique and historic collaboration. The combination of excellent academic science with industrial drug discovery know how has been a long term objective of Sygnature Discovery and it is excellent news that we will be working closely with our colleagues at the University of Nottingham, BioCity Scotland and others. This initiative has the potential to be transformational for drug discovery in Europe and should create a new engine for modern discovery. Long-term benefits will hopefully include improved medicines and a strong industrial-academic network with unique expertise.” Further information See MTB Europe news: BioCity Scotland to be UK hub for €196m European drug discovery project.
|
|||